HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma

被引:87
作者
Buglio, Daniela [1 ]
Khaskhely, Noor M. [1 ]
Voo, Kui Shin [2 ]
Martinez-Valdez, Hector [2 ]
Liu, Yong-Jun [2 ]
Younes, Anas [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
HISTONE DEACETYLASE INHIBITOR; T-CELL EXPANSION; ANTITUMOR IMMUNITY; CUTTING EDGE; IN-VIVO; APOPTOSIS; TUMOR; SUPPRESSION; MGCD0103; THERAPY;
D O I
10.1182/blood-2010-08-303701
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In Hodgkin lymphoma (HL), the malignant cells are surrounded by a large number of reactive infiltrating inflammatory cells, including OX40-expressing T cells and interleukin 10 (IL-10)-producing regulatory T (T-reg) cells. These T-reg cells can suppress the immune response and thus contribute to the maintenance of immune tolerance and to insufficient antitumor response. The engagement of OX40L with the OX40 receptor is essential for the generation of antigen-specific memory T cells and for the induction of host anti-tumor immunity. In the present study, we investigated whether histone deacetylase inhibitors (HDACis) may induce a favorable antitumor immune response by regulating the expression of OX40L in HL. We found that HDACis up-regulated OX40L surface expression in HL cell lines in a dose-dependent manner. Small interfering RNAs (siRNAs) that selectively inhibited HDAC11 expression, significantly up-regulated OX40L and induced apoptosis in HL cell lines, and silencing HDAC11 transcripts increased the production of tumor necrosis-alpha (TNF-alpha) and IL-17 in the supernatants of HL cells. Furthermore, HDACI-induced OX40L inhibited the generation of IL-10-producing type 1 T-reg cells. These results demonstrate for the first time that HDAC11 plays an essential role in regulating OX40L expression. Pharmacologic inhibition of HDAC11 may produce a favorable antitumor immune response in patients with HL. (Blood. 2011;117(10):2910-2917)
引用
收藏
页码:2910 / 2917
页数:8
相关论文
共 46 条
  • [1] PCI-24781 Induces Caspase and Reactive Oxygen Species-Dependent Apoptosis Through NF-κB Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells
    Bhalla, Savita
    Balasubramanian, Sriram
    David, Kevin
    Sirisawad, Mint
    Buggy, Joseph
    Mauro, Lauren
    Prachand, Sheila
    Miller, Richard
    Gordon, Leo I.
    Evens, Andrew M.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (10) : 3354 - 3365
  • [2] Cytotoxic T lymphocyte therapy for Epstein-Barr virus Hodgkin's disease
    Bollard, CM
    Aguilar, L
    Straathof, KC
    Gahn, B
    Huls, MH
    Rousseau, A
    Sixbey, J
    Gresik, MV
    Carrum, G
    Hudson, M
    Dilloo, D
    Gee, A
    Brenner, MK
    Rooney, CM
    Heslop, HE
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 200 (12) : 1623 - 1633
  • [3] Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines
    Buglio, Daniela
    Georgakis, Georgios V.
    Hanabuchi, Shino
    Arima, Kazuhiko
    Khaskhely, Noor M.
    Liu, Yong-Jun
    Younes, Anas
    [J]. BLOOD, 2008, 112 (04) : 1424 - 1433
  • [4] NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma
    Catley, L
    Weisberg, E
    Tai, YT
    Atadja, P
    Remiszewski, S
    Hideshima, T
    Mitsiades, N
    Shringarpure, R
    LeBlanc, R
    Chauhan, D
    Munshi, NC
    Schlossman, R
    Richardson, P
    Griffin, J
    Anderson, KC
    [J]. BLOOD, 2003, 102 (07) : 2615 - 2622
  • [5] CROFT M, ANN REV IMMUNOL, V28, P57
  • [6] MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
    Fournel, Marielle
    Bonfils, Claire
    Hou, Yu
    Yan, Pu Theresa
    Trachy-Bourget, Marie-Claude
    Kalita, Ann
    Liu, Jianhong
    Lu, Ai-Hua
    Zhou, Nancy Z.
    Robert, Marie-France
    Gillespie, Jeffrey
    Wang, James J.
    Ste-Croix, Helene
    Rahil, Jubrail
    Lefebvre, Sylvain
    Moradei, Oscar
    Delorme, Daniel
    MacLeod, A. Robert
    Besterman, Jeffrey M.
    Li, Zuomei
    [J]. MOLECULAR CANCER THERAPEUTICS, 2008, 7 (04) : 759 - 768
  • [7] Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family
    Gao, L
    Cueto, MA
    Asselbergs, F
    Atadja, P
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (28) : 25748 - 25755
  • [8] Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death
    Georgakis, GV
    Li, Y
    Rassidakis, GZ
    Martinez-Valdez, H
    Medeiros, LJ
    Younes, A
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (02) : 584 - 590
  • [9] Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors
    Gloghini, Annunziata
    Buglio, Daniela
    Khaskhely, Noor M.
    Georgakis, Georgios
    Orlowski, Robert Z.
    Neelapu, Sattva S.
    Carbone, Antonino
    Younes, Anas
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2009, 147 (04) : 515 - 525
  • [10] OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor
    Gough, Michael J.
    Ruby, Carl E.
    Redmond, William L.
    Dhungel, Birat
    Brown, Alexis
    Weinberg, Andrew D.
    [J]. CANCER RESEARCH, 2008, 68 (13) : 5206 - 5215